08.05.2024 – 03:42
Corvia Medical, Inc.
Tewksbury, Massachusetts (ots/PRNewswire)
Two-year echocardiographic data confirm positive effects of atrial shunt therapy on cardiac structure and function
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication of groundbreaking two-year echocardiographic data from the REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial Shunt in JAMA Cardiology Provide insight into the effects of a shunt on the heart.
The study demonstrated beneficial long-term effects of atrial shunting on cardiac structure and function in patients with heart failure with preserved or slightly reduced ejection fraction (HFpEF/HFmrEF). The analysis found that the atrial shunt resulted in favorable cardiac remodeling and restoration of normal cardiac function, which in turn led to improved clinical outcomes and prognosis.
The analysis also showed more favorable remodeling in pre-defined responders compared to non-responders and confirmed that patients without latent pulmonary vascular disease and without a pacemaker are most likely to benefit from atrial shunt therapy.
“We now have two years of evidence of reverse remodeling in patients with an atrial shunt, with more pronounced improvements in cardiac structure and function – and associated clinical benefit – in previously defined responders compared to non-responders,” said Dr. Sanjiv Shah, director of the HFpEF program at Northwestern University School of Medicine and principal investigator for the study. “These data not only provide insight into the long-term effects of atrial shunting, but also represent the largest and most comprehensive echocardiographic follow-up study of a device or pharmacological study in HFpEF and HFmrEF to date.
“The results of our study support the referral of eligible patients to RESPONDER-HF, a randomized, sham-controlled trial currently underway in the United States, Europe and Australia to provide the evidence needed for FDA approval of the Corvia Atrial Shunt for millions of heart failure patients to get.”
About heart failure (HF) and the Corvia Atrial Shunt
More than 26 million people worldwide suffer from heart failure, most of them HFpEF, and represent the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary cause of HF symptoms in HFpEF patients, by creating a pathway between the left and right atria, thereby reducing HF events and the quality of life can be improved. The Corvia Atrial Shunt received breakthrough device designation from the FDA in 2019. For information about participating in the RESPONDER-HF study, visit https://treatmyheartfailure.com.
About Corvia Medical, Inc.
Corvia Medical, Inc. is revolutionizing the treatment of heart failure with novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, privately held Corvia is committed to changing the standard of care for heart failure and giving patients a new lease on life. visit
Media contact:
Ms. Lisa
+1 978-654-6120
[email protected] View original content:
Original content from: Corvia Medical, Inc., transmitted by news aktuell